Multiple studies showed no benefit of immunosuppressive agents (MMF, CYC), so this study is standing alone with relatively small number and limited centers. Better to role those IgAN patients in current ongoing studies, yet, I won't blame trying MMF if appropriate conservative management is optimize...

As far as I know, the success of MMF in treating IgA nephropathy was only reported in Chinese populations which is reflected in the KDIGO guidelines. For patients intolerant of steroids who cannot be enrolled in clinical trials, enteric steroids, and sparsentan have shown promise.